Olanzapine-Induced Weight Gain in Patients With First-Episode Schizophrenia: A Double-Blind, Placebo-Controlled Study of Fluoxetine Addition

2002 ◽  
Vol 159 (6) ◽  
pp. 1058-1060 ◽  
Author(s):  
Michael Poyurovsky ◽  
Artashes Pashinian ◽  
Irit Gil-Ad ◽  
Rachel Maayan ◽  
Michael Schneidman ◽  
...  
Keyword(s):  
Weight Gain ◽  
Controlled Study ◽  
First Episode ◽  
Double Blind ◽  
Double Blind Placebo ◽  
First Episode Schizophrenia

Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study

2014 ◽  
Vol 53 ◽  
pp. 133-140 ◽  
Author(s):  
Amirhossein Modabbernia ◽  
Parvaneh Heidari ◽  
Robabeh Soleimani ◽  
Abdolrasoul Sobhani ◽  
Zahra Atrkar Roshan ◽  
...  
Keyword(s):  
Side Effects ◽  
Controlled Study ◽  
First Episode ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Metabolic Side Effects ◽  
First Episode Schizophrenia

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study

2007 ◽  
Vol 192 (3) ◽  
pp. 441-448 ◽  
Author(s):  
Michael Poyurovsky ◽  
Camil Fuchs ◽  
Artashez Pashinian ◽  
Aya Levi ◽  
Sarit Faragian ◽  
...  
Keyword(s):  
Weight Gain ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled Trial of Metformin for Antipsychotic-Induced Weight Gain in Patients with First-Episode Psychosis: A Pilot Study

2021 ◽  
Vol 19 (1) ◽  
pp. 137
Author(s):  
Charmaine Tang ◽  
Yi Chian Chua ◽  
Edimansyah Abdin ◽  
Mythily Subramaniam ◽  
Swapna Verma
Keyword(s):  
Weight Gain ◽  
Pilot Study ◽  
Controlled Trial ◽  
First Episode Psychosis ◽  
First Episode ◽  
Antipsychotic Treatment ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Episode Psychosis

Excessive weight gain and cardiometabolic dysfunction are common and clinically relevant side effects of antipsychotic medications. In this pilot study, we aimed to establish the feasibility of using metformin and its effectiveness in managing antipsychotic-induced weight gain in patients with first-episode psychosis (FEP) on follow-up with the Singapore Early Psychosis Intervention Programme in a 24-week, randomized, double-blind, placebo-controlled trial, to ascertain the effects of metformin discontinuation on body weight and evaluate the safety and tolerability of metformin. Participants between the ages of 16 and 40 with FEP assessed as clinically stable and who had gained ≥5% of their pre-drug weight after initiation of the antipsychotic treatment were recruited from outpatient clinics between April 2015 and April 2018. Seventeen participants met all the inclusion criteria and were randomized to receive metformin (n = 8) or the placebo (n = 9) at Week 0, with follow up assessments at Weeks 3, 6, 12, 24, and 36. Metformin was generally well-tolerated. Participants in the metformin arm were able to control their weight better than participants receiving the placebo, an effect that did not persist after discontinuation. Our results support the use of metformin as a safe and tolerable weight control measure in a typical outpatient sample of young people with FEP.

Sign in / Sign up

Export Citation Format

Share Document